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Interleukin 4 (IL-4) exerts a decisive role in the 
coord.ination of proteelive immune responses against 
parasites, particularly helminths. A disregulation of ll.r4 
function is possibly involved in the genesis of allergic 
disease states. The search for important amino acid 
residues in human ll.r4 by mutational analysis of charged 
invariant amino acid positions identified two distinct 
functional sites in the 4-helix-bundle protein. Site 1 was 
marked by amino acid substitutions of the glutamic acid 
at position 9 in helix A and arginine at position 88 in helix 
C. Exchanges at both positions led to IL-4 variants 
deficient in binding to the extracellular domain of the ll.r4 
receptor (IL-4ReJ. In parallel, up to 1000-fold increased 
concentrations of this type of variant were required to 
induce T -cell proliferation and B-eeil CD23 expression. 
Site 2 was marked by amino acid exchanges in helix D 
at positions 121, 124 and 125 (arginine, tyrosine and 
serine respectively in the wild-type).ß.A variants affected 
at site 2 exhibited partial agonist activity during T -cell 
proliferation; however, they still bound with high affinity 
to IL-4Rex. [The generation of an IL-4 antagonist by 
replacing tyrosine 124 with aspartic acid has been 
described before by Kruse et al. (1992) (EMBO }., 11, 
3237-3244)]. These findings indicate that IL-4 functions 
by bind.ing IL-4Rex via site 1 which is constituted by 
residues on helices A and C. They further suggest that 
the association of a second, still undetined receptor 
protein with site 2 in helix D activates the receptor system 
and generates a transmembrane signal. 
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lntroduction 
Interleukin 4 (IL-4) represents a typical cytokine which 
triggers and coordinates the immune response against certain 
parasites by causing the growth and differentiation of a 
variety of cells ( for review see Paul, 1991 ; Romagnani, 
1992; Boulay and Paul, 1992; Scott, 1993). Mast cells, a 
T -cell subset and thymocytes can synthesize IL-4. However, 
the primary cellular source of IL-4 after helminth infection 
is unknown. In cell cultures the responses to IL-4 are 
manifold; they include notably the induction of IgE (e.g. 
Romagnani, 1991), MHCIT (e.g. Noelle et al., 1984) and 
CD23 (e.g. Kikutani, 1986) in B-cells, the induction of V-
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CAM in capillary endothelial cells ( Schieimer et al. , 1992) 
or the expression of 15-lipoxygenase in monocytes (Conrad 
et al., 1992). In addition, IL-4 promotes DNA synthesis and 
short-term proliferation of T-cells (Hu-Li et al., 1987), 
thymocytes (Barcena et al., 1991), fibroblasts (Monroe 
et al., 1988) and capillary endothelial cells (Toi et al., 1991). 
In whole animals the loss of the IL-4 gene (Kühn et al. , 
1991; Kopf et al., 1993) or the neutralization ofiL-4 activity 
(Urban et al., 1991) abolishes the generation oftype 2 helper 
T -cells (T H2-cells) and the synthesis of IgE. A 
pathophysiological role of IL-4 is indicated in transgerne mice 
where the overexpression of IL-4 Ieads to allergic-like 
inflammatory disease states (Tepper et al., 1990). 
Transfeeted tumour cells expressing IL-4 are rejected in vivo 
by recruited host granulocytes and macrophages (Tepper 
et al., 1989). For these reasons IL-4 itself as well as IL-4 
antagonists may be suitable for a number of therapeutic 
applications. 
IL-4 receptors have been identified on a variety of cell 
types and celllines (for review see Beckmann et al., 1992). 
Typically, IL-4 binding sites occur with a frequency of 
300-3000 per cell and exhibit an apparently homogeneous 
dissociation constant, K0 , of 50-100 pM. Different cells 
and cellular responses, however, show large differences in 
sensitivity to IL-4. Concentrations effecting half-maximal 
responses (EC50 values) were reported to range from 0.5 
to 200 pM (e.g. Garrone et al., 1991; Rigley et al., 1991; 
Kruse et al., 1992). The IL-4 activities are mediated by a 
receptor system for which up to now only a single protein 
has been identified. In human cells, this IL-4 binding protein 
consists of an extracellular domain of 207 amino acid 
residues, a 24 residue transmembrane segment and an 
unusually large intracellular domain of 569 amino acid 
residues (Galizzi et al., 1990; Idzerda et al., 1990). The 
extracellular domain alone binds IL-4 with a K0 of -100 
pM. As a member of the haematopoietin receptor family 
(Bazan, 1990) it is composed of two fibronectin type m 
modules (Bork and Doolittle, 1992). In responsive celllines 
and activated T -cells IL-4 induces a specific pattem of protein 
tyrosine phosphorylation which differs from that produced 
by IL-3 (Wang et al., 1992) or IL-2 (lzuhara et al., 1993). 
Deletion analysis indicates that a sequence of amino acids 
from position 97 to position 137 in the intracellular domain 
is required for transmission of the growth signal in the Ba/F3 
cell line (Harada et al., 1992). 
The three-dimensional structure of human IL-4 has 
recently been determined in solution (Redfield et al., 1991; 
Powerset al., 1992; Smith et al., 1992; T.Müller, W.Sebald 
arid H.Oschkinat, submitted) andin crystallized form (Walter 
et al., 1992a; Wlodawer et al., 1992). A 4-helix-bundle 
structure with an up-up-down-down connectivity has been 
established. A short ß-sheet occurs between two long loops 
connecting helices A/B and helices C/D. Replacement of 
cysteines in human IL-4 by threonine residues revealed that 
the disulfide bridge forrned by cysteines at positions 46 and 
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Table I. V ariants of human IL-4 and their functional activities 
IL-4 variant EC50 value (nM) ~ax (%) Relative IC50 
IL-4 0.14 100 1 
H1Q 0.12 97 0.9 
D4N 0.13 96 0.4 
E9Q 3.1 98 170 
E9K 320 101 1400 
E26Q 0.09 95 0.9 
K37Q 0.07 98 0.7 
E41Q 0.19 98 0.7 
E43Q 0.07 105 0.7 
R47Q 0.17 98 1.0 
R53Q 0.13 98 8.0 
H59Q 0.76 98 1.9 
K61Q 0.1 99 1.5 
R85Q 0.07 98 1.5 
R88Q 2.5 90 210 
R88D 400 >69 2900 
E103Q 0.35 104 0.8 
E114Q 0.09 96 0.7 
K117Q 0.07 99 0.7 
M120D 12 63 
R121D 0.13 31 1.3 
K123D 0.24 96 1.5 
S125D 0.14 30 1.4 
C127D 1.2 100 5.3 
S128D 0.14 95 1.0 
Y124D <0.5 3.0 
The nurober in the designation of the variants indicates the position 
altered by in vitro mutagenesis. The amino acid originally present in 
IL-4 is indicated by the firSt Ietter and the substituted amino acid by 
the second Ietter, both in the one-letter code. The locations of the 
altered positions are indicated in Figure 6. Concentrations of the IL-4 
proteins effecting half-maximal proliferation of T -cells (EC50 values) 
and the maximal response obtained at saturation Ievels in relation to 
nonnal IL-4 <Rmax values) indicate the functional activities of the 
variants. The receptor affinities of the variants as measured during 
competitive radioligand binding to Raji cells are listed under relative 
IC50• 
99 is essential for the folding of functional IL-4, whereas 
the other two disulfide bridges formed by cysteines 24/65 
and 3/127 are less important (Kruse et al., 1991). Antagonist 
or partial agonist variants of human IL-4 were obtained by 
replacing tyrosine 124 with aspartic acid, glycine, asparagine 
or Iysine (Kruse et al., 1992). Receptor-binding residues bad 
not yet been experimentally identified in human IL-4. Mouse 
IL-4 variants deficient in receptor binding and/or activation 
have been reported recently (Morrison and Leder, 1992). 
The present results were obtained after a systematic search 
for functionally important amino acid residues in human 
IL-4. Remarkably, the mutational analysis produced two 
types of variants impaired in either receptor binding or 
receptor activation. The location and functional role of the 
important amino acid residues identified in human IL-4 
suggest similarities with other 'small' cytokines of the 
4-helix-bundle protein family, such as granulocyte macro-
phage colony stimulating factor (GM-CSF) (Diederichs 
etal., 1991; Walter etal., 1992b) or IL-2 (Bazan, 1992; 
McKay, 1992; Mott et al., 1992). Interestingly, in contrast 
to the human growth hormone (hGH), which represents the 
prototype of a 'large' 4-he1ix-bundle protein, the antagonism-
determining site of human IL-4 is located on helix D and 
not, as in hGH, on the site formed by helices A and C 
(DeVos et al., 1992; Fuh et al. 1992). 
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Results 
Construction and isolation of /L-4 variants 
The IL-4 variants constructed and analysed during the present 
study are compiled in Tab1e I. The positions to be modified 
were selected on the basis of the following considerations. 
Acidic and basic amino acid side chains are usual1y 
exposed at the surface of a protein. Consequently, some of 
the 14 acidic and 27 basic residues present in human IL-4 
might be expected to be involved in receptor binding. A 
subset of 16 of these charged amino acid residues is invariant 
or highly conserved in the amino acid sequences of the IL-4 
from man, mouse, rat, cow and pig (McKnight et al. , 1991; 
Bailey et al., 1993). They appear, therefore, tobe of special 
and general importance despite the species-specificity of 
IL-4. Only these evolutionarily conserved positions were 
selected for mutagenesis. The charged residues were replaced 
by glutamine and in one case by asparagine. 
Another set of variants was generated by replacing residues 
near tyrosine 124 with aspartic acid. In previous experiments 
replacements of this residue by other amino acid residues 
and especially by aspartic acid produced partial agonistic or 
antagonistic variants (Kruse et al. , 1992). Side chains of 
residues at positions 120, 121, 123, 125, 127 and 128 would 
be juxtaposed to tyrosine 124 on the surface of a helix. It 
was therefore investigated whether an aspartyl residue at 
these positions might generate partial agonism of the protein. 
The variants shown in Table I could be expressed in 
Escherichia coli in large amounts as inclusion bodies. They 
were subjected to a renaturation protocol and highly purified 
by HPLC (see Kruse et al. , 1991). The final yields were 
similar (0.5 -2.0 mg per litre of culture) to that obtained 
with IL-4. Exceptions were variants M120D and C127D 
which refolded poorly and could be recovered only in low 
amounts. Variant M120D still contained major contaminants 
after the final HPLC purification step. 
/dentification of /L-4 variants with altered properties 
during T-ee// proliferation 
Most of the IL-4 variants in the first group induced the 
proliferation of activated T -cells similarly to IL-4 with a half-
maximal response at a concentration of 70-280 pM (see 
Table 1). Four variants, however, clearly exhibited irnpaired 
activity (Figure 1A). lncreased concentrations of variants 
E9Q and R88Q were necessary to stimulate T -cell 
proliferation. At sufficiently high doses the maximal response 
obtained was equal to that produced by IL-4. A more drastic 
change at these positions in variants E9K and R88D increased 
the EC50 > 1000-fold. Nevertheless, at saturating 
concentrations of variant E9K the maximal IL-4 response 
was produced. Accordingly, these variants modified at 
positions 9 or 88 are pure 'EC50 variants'. Repeatedly, the 
activity of variant R88D decreased at concentrations above 
1 JLM. Therefore, the maximal response could not be 
established in the T -cell system. Such a decrease in activity 
was observed also with IL-4 and the other EC50 variants, 
although only at concentrations above 10 ~tM (not shown). 
It has not yet been investigated whether this represents the 
inhibitory activity of a contaminant or an self-antagonistic 
activity of the IL-4 proteins. The latter has been observed 
with hGH (Fuh et al., 1992). 
Among the second group of IL-4 mutant proteins with 
Substitutions near position 124, two 'Rmax variants' were 
found exhibiting partial agonist activity (Figure lB). Variants 
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Fig. 1. Proliferation of activated T -cells (PHA blasts) in response to 
increasing doses of IL-4 (e) and (A) EC50 variants E9Q (0), R88Q 
<•>. E9K (~) and R88D (A), or (B) Rroax variants R121D (0), 
Yl24D (0) and Sl2SD (~). 
R121D and S125D stimulated T-cell proliferation with 
EC50 values of 130 and 140 pM respectively, similar to that 
of IL-4; the maximal response, Rmax, however, was only 
30% of the maximal IL-4 response. These variants are 
therefore defective in receptor activation. In this respect 
R121D and Sl25D resemble variants Y124G, Y124N and 
Y124K which have been studied previously (Kruse et al., 
1992). The Rmax variants R121D and S125D arealso partial 
antagonists. IL-4-stimulated T -cell proliferation could be 
inhibited by these variants down to a value corresponding 
to their maximal partial agonist activities. The competitive 
inhibitor constants, Ki, were 300-600 pM, not much 
higher than the EC50 values of their partial agonist activities 
(data not shown). These results support the conclusion that 
these variants have a reduced signaHing activity. 
Remarkably, the drastic Substitutions generated in variants 
Kl23D and Sl28D did not measurably change the functional 
properties of these proteins under our experimental 
conditions. The variant C127D exhibited a modest increase 
in the EC50 value. The significance of this remains unclear. 
The same applies for the slightly reduced Rmax value and 
the 100-fold increased EC50 value of variant M120D. 
Considering the poor yields after renaturation and 
purification, structural instability and major folding defects 
appear to be possible for C127D and especially for the 
Ml20D variant (see Discussion). 
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Fig. 2. Competition for binding to the IL-4 receptor of Raji cells 
between radiolabelled IL-4 and unlabelled IL-4 ( •) or (A) ECso 
variants E9Q (0), R88Q <•>. E9K (~) and R88D (A), or (B) Rroax 
variants Rl21D (0), Yl24D (0) and S12SD (~). 
Receptor binding of /L-4 vsrisnts studied with the 
receptor of Rsji cells 
The affinity of the IL-4 variants for the IL-4 receptor present 
in the Raji Iymphoma cellline was analysed by competitive 
radioligand binding at 4°C employing 0.2-0.5 nM 
[125J]IL-4 as shown in Figure 2. Variants altered at positons 
9 and 88 exhibited much higher K0 values than did IL-4 
(see also Table 1). The relative IC50 values (i.e. IC50 
variant/IC50 IL-4) of E9Q and R88Q were -200, those of 
variants E9K and R88D were -2000. The increase in K0 
of the individual variants is sirnilar with E9K and R88D or 
-10-fold larger with E9Q and R88Q than the increase in 
the EC50 values. Remarkably, the Rmax variants Rl21D, 
Sl25D (see TableI and Figure 2B) and Yl24D (Kruse 
et al., 1992) bind to the IL-4 receptor of Raji cells with a 
K0 comparable to that of normal IL-4. The inefficient 
receptor activation is not reflected by an altered apparent 
K0 . While it is unknown whether Raji cells express a 
functional IL-4 receptor, previous experiments employing 
primary human T -cells and B-cells have also established that 
the highly deficient Rmax variant Yl24D binds to the 
receptor of these cells with a K0 of - 300 pM. This value 
is 3-fold larger than the K0 of IL-4, 100 pM (Kruse et al., 
1992), which has been determined not only in primary cells 
but also in a variety of IL-4-responsive cell lines (see 
Beckmann et al., 1992). 
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Dose-response measurements of EC50 variants 
during a highly sensitive 8-ce/1 assay 
Human IL-4 induces the expression of CD23 (Fcdl) in 
purified B-cells at EC50 values of 2- 10 pM (Kruse et al. , 
1992). This B-eeil response is -50 times more sensitive 
than the proliferative response of T-cells (see above). The 
induction of CD23 on B-cells possibly requires a very low 
occupancy of the IL-4 receptor. lt is also possible that a 
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Fig. 3. Induction of the low affinity FeE receptor (CD23) on B-cells in 
response to increasing doses of IL-4 <•> or variants E9Q (0), R88Q 
<•>. E9K (b.) and R88D (A). (A) Mean CD23 content of B-cells. 
(B) Number of CD23 positive B-cells as percent of maximal response. 
different receptor system exists in B-cells; this is supported 
by the observation that IL-4-induced expression of CD23 
on human B-cells is regulated independently from that of 
IgM (Rigley et al. , 1991). It was therefore interesting to 
examine how far the EC50 variants show a similar increase 
in EC50 during the B-eeil assay and during the T -cell 
response described above. 
The experiment presented in Figure 3 yielded EC50 
values of 2. 7 pM for the IL-4-dependent induction of the 
mean CD23 content, and 0.3 pM for the induction of the 
percentage of CD23 positive cells, in accordance with 
previously described experiments (Kruse et al., 1992). The 
variants E9Q and R88Q produced a half-maximal response 
only at 30-50 times higher concentrations (see also 
Table m. The concentrations of E9K or R88D necessary 
for half-maximal CD23 induction were 2000-10 000 times 
higher than those required for IL-4. As statistically evaluated 
and compiled in Table II, these relative EC50 values are 
remarkably similar to those observed during the T -cell assay, 
despite the fact that the absolute EC50 values for the 
responses of the two cellular systems differ by about two 
orders of magnitude. These observations give further support 
to the view that the sarne IL-4 receptor system operates in 
B- and T -cells at least as far as the Iigand binding and 
receptor activation is concemed. 
Receptor binding of /L-4 variants as studied with the 
isolated extracellular domain of the /L-4 receptor 
The extracellular domain of the human IL-4 receptor 
(IL-4ReJ comprising amino acid residues 1-207 of the 
mature receptor proteinwas expressed in CHO cells and 
highly purified by affinity chromatography on IL-4-
Sepharose. A solid-phase assay employing streptavidin-
coated wells of a microtitre plate and immobilized 
biotinylated IL-4Rex was developed in order to analyse the 
binding properties of IL-4 variants. Such a system is more 
convenient to handle than whole cells. Furthermore, the 
properties of immobilized IL-4Rex can be compared with 
those of the functional receptor. Analysis of purified 
IL-4Rex using chemical crosslinking and gel chromato-
graphy revealed no oligomeric forms of the protein 
(S.Amold and W.Sebald, unpublished observation). Thus, 
IL-4Rex becomes immobilized probably as a monomer, and 
a 1 : 1 interaction of IL-4 protein and the receptor can be 
Table ß. Quantitative evaluation of altered characteristics in IL-4 EC50 variants and Rmax variants 
Protein T -cell proliferation B-cell C23 induction Competitive radioligand binding 
Relative EC50 R.nax (%) Mean CD23 content % CD23+ cells Raji cells IL-4Rex 
Relative EC50 Relative IC50 
IL-4 I (1.9) 107 :± 6 I (1.6) (2.5) (1.3) (1.3) 
E9Q 22 (1.5) 98 :± 7 35 (1.3) 48 (1.7) 170 (1.9) 410 (1.3) 
R88Q 18 (1.4) 90 :± 9 28 (1.6) 38 (3) 210 (2.2) 1400 (2) 
E9K 2300 (1.3) 101 :± 9 2000 (1.2) 3 200 (1.7) 1400 (2.6) 1700 (2) 
R88D 2900 (2.6) >69 :± 7 7600 (1.3) 11000 (1.9) 2900 (2) 4800 (2.2) 
RI21D 0.7 (1.5) 31 :± 19 1.3 (1.6) 0.6 (1.7) 
YI24D <0.5 3 (1.7) 0.7 (1.5) 
S125D 0.7 (1.5) 30 :± 19 1.4 (1.5) 1.5 (1.5) 
The EC50 and IC50 values are distributed log nonnal (see Materials and methods). The numbers in brackets are the standard deviations (in multiples of 
the mean values) calculated from log EC50 :± log SD or log IC50 :± log SO. 
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studied without interference with oligomerization and/or 
activation steps. This would permit the residues modified 
in the EC50 and Rmax variants to be assigned specifically to 
binding functions associated with the cloned IL-4 receptor 
protein. 
Saturation binding of [ 125I)IL-4 at room temperature is 
described in Figure 4. Half-maximal binding is observed at 
100 pM IL-4. Nonspecific binding determined in the 
presence of 500 nM unlabelled IL-4 is < 10%. The K0 
value observed with immobilized IL-4Rex is remarkably 
similar to the K0 values of 50- 100 pM found for the 
binding of IL-4 to whole Raji cells, B-cells or T -cells at 4 °C 
(e.g. Kruse et al., 1992). 
Competitive radioligand binding experiments revealed 
(Figure 5A) that relative to IL-4 the EC50 variants E9Q and 
R88Q bound to IL-4Rex with a 410-fold and 1400-fold 
increased K0 respectively. The relative K0 s of E9K and 
R88D were slightly higher. These results clearly indicate 
that a defective interaction with the extracellular domain of 
the known IL-4 receptor protein causes the increased EC50 
values of this group of variants. 
The binding properties of Rmax variants R121D, Sl25D 
and Y124D (Figure SB) clearly differ from those of the 
EC50 variants described above. They bind to immobilized 
IL-4Rex with a K0 similar to. that of normal IL-4. 
Remarkably, the inefficient receptor activation is not 
reflected by an altered interaction between this type of IL-4 
variant and the isolated receptor protein. 
A quantitative evaluation and a comparison of the altered 
responses of EC50 variants (and Rmax variants) are presented 
in Table ll. The highly deficient variants E9K and R88D 
exhibit a loss of function that is largely the same during both 
the biological and the binding assays. The Standard deviations 
shown in brackets reveal no significant differences between 
the experimental data. The moderately deficient variants, 
E9Q and R88Q, however, appear tobe similarly altered only 
during the biological T- and B-eeil assays whereas the 
binding affinity to Raji cells or IL-4Rex is clearly reduced 
more. This statistically significant difference remains 
unexplained. Similar effects have been observed before in 
the IL-2 system where variants deficient in binding to the 
a subunit of the receptor (Tac) have normal EC50 values 
during T-cell proliferation (e.g. Weigel et al., 1989; 
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Zurawski and Zurawski, 1989). Considering the different 
experimental set-ups during competitive radioligand binding 
and during the biological response measurements, a more 
complex effect of amino acid substitutions during the cell 
culture experiments appears to be possible. For example, 
the IL-4 system in B- and T -cells is probably not in 
thermodynamic equilibrium, since the receptor off-rates are 
lower than the intemalization rates for the Iigand- receptor 
complex (Galizzi et al., 1989; Liang et al., 1992). 
Consequently, the biological responses are largely 
determined by the receptor on-rate. It can be visualized that 
the on- and off-rates are altered to a different extent in the 
E9Q and R88Q variants. 
Discussion 
The altered biological activities and the receptor binding 
properties of the IL-4 variants identified during the present 
study indicate that human IL-4 provides functionally distinct 
sites for interactions with receptor proteins. One of these 
sites determines the signalling efficacy of IL-4, since amino 
acid exchanges Iead to the partial agonistic Rmax variants. 
The other site determines the binding to IL-4Rex and 
accordingly variants affected at this site show increased 
EC50 values. The 'signalling site' is provided by an area 
around the side chains of arginine 121, tyrosine 124 and 
serine 125 in helix D. The 'binding site' for IL-4Rex is 
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Fig. 6. Schematic drawings of the three-dimensional structure of human IL-4 showing views of helices A and C (left) and helices D and A (right). 
Closed circles indicate the approximate locations of 'binding residues' glutamic acid 9 (E9) and arginine 88 {R88) as weil as of 'signalling residues' acid 
arginine 121 {Ri21), tyrosine 124 (Y124) and serine 125 (S125). (Arginine 88 is located at the back of the protein in the D-A view.) Open circles 
designate the other positions which so far have been altered by amino acid subsitutions [see TableI and Kruse et al., (1991).] 
marked by glutamic acid 9 in helix A and arginine 88 in 
helix C. The location of these residues is depicted in the two 
schematical views of human IL-4 in Figure 6. The 
established three-dimensional structure of human IL-4 shows 
that these amino acid side chains are exposed completely 
or, in the case of tyrosine 124, partially at the surface of 
the protein (e.g. T.Müller, W.Sebald and H.Oschkinat, 
submitted). Furthermore, the 'binding residues' at positions 
9 and 88 are juxtaposed, as are the 'signalling residues' at 
positions 121, 124 and 125. The functional sites marked by 
the mutational analysis are therefore compatible with the 
topology and location of the involved residues. Amino acid 
Substitutions at other positions which have been analysed in 
the present and a previous study (Kruse et al. , 1992) did 
not produce major functional alterations. A few substitutions 
interfered with the folding and/or stability of the protein. 
These negative results do not exclude the possibility that 
residues at these positions are of functional importance. The 
replacements performed up to now with only one single 
amino acid residue may be too insignificant to cause 
measurable functional defects. 
Severallines of evidence support the view that the amino 
acid substitutions causing the functionally deficient IL-4 
variants discussed above do not produce major alterations 
in the protein fold. (i) The Rmax variants bind with largely 
unchanged affmity for IL-4Rex· Thus, the alterations in 
helix D apparently remain essentially confined to the 
'signalling site', and they leave the 'binding site' intact (see 
also T.Müller, W.Sebald and H.Oschkinat, submitted). (ii) 
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The EC50 variants as weil as the Rom variants are renatured 
and purified from inclusion bodies in yields similar to IL-4. 
(iii) When reanalysed by HPLC, the protein is eluted as a 
symmetrical peak at the IL-4 retention time. (iv) Further-
more, certain monoclonal antibodies against human IL-4, 
which are sensitive to structural perturbations, bind with 
normal affinity to these variants (Reusch et al. , unpublished 
Observations). 
Our conclusions are at variance with some of the 
interpretations deduced from the study of mouse IL-4 mutant 
proteins (Morrison and Leder, 1992). Mouse IL-4 variants 
were generated by alanine-scanning mutagenesis and 
expressed in CHO cells as fusion proteins with alkaline 
phosphatase. The mousevariant El2A modified at glutamic 
acid 12 (which corresponds to human IL-4 glutamic acid 9) 
exhibited a > 100-fold reduced bioactivity and receptor 
binding affmity. lt was suggested that this residue is 
important for structural integrity. A series of mouse IL-4 
variants with modifications in helix D (L104A, Dl06A, 
F107 A and L111A) each lost both binding and biological 
function. It was suggested that helix D was part of the 
receptor binding domain of mouse IL-4 and, more 
specifically, it was proposed that the side chains of leueine 
104, aspartic acid 106, phenylalanine 107 and leueine 111 
contributed most to the binding interactions in this region. 
Perhaps some of these interpretations were premature. It is 
reasonable to assume that the three-dimensional structures 
of mouse and human IL-4 are largely comparable, despite 
species-specificity in receptor binding and bioactivity. 
According to the now available structural data on human 
IL-4, the side chains of the invariant leueine 104, 
phenylalanine 107 and leueine 111 areintegral constitutents 
of the hydrophobic core and consequently would not be 
available for receptor interactions. On the other band, despite 
the determinants for species-specificity in the first 16 amino 
acid residues of mouse IL-4, it is quite possible that the 
invariant side chain of glutamic acid 12 functions in receptor 
bindingalso in mouse IL-4. Adefinite decision, however, 
requires a structural analysis of these mutant proteins. 
Interestingly, a deletion of the last C-terminal amino acids 
of mouse IL-4 generates a variant highly deficient in 
bioactivity but retaining normal receptor-binding affmity. 
The deleted residues can be aligned to Iysine 123 and also 
tyrosine 124 and serine 125 of human IL-4 functioning in 
receptor activation. Thus, a 'signalling site' appears tobe 
present also at the corresponding positions in the helix D 
of mouse IL-4. 
Human GM-CSF and human IL-2 are folded remarkably 
similarly to human IL-4 despite the fact that the amino acid 
sequences are only vaguely related. All three proteins consist 
of -130 amino acid residues. The 4-helix-bundle structures 
show the same up-up-down-down connectivity ('double-
overhand' topology), and the long AB and CD loops are 
connected by a short ß-sheet. Parts of their three-dimensional 
structures are nearly superimposable (Wlodawer et a/., 1992; 
T.Müller, W.Sebald and H.Oschkinat, submitted). Some 
variability exists in the length of the N -terminal end of helix 
C which is shorter in GM-CSF, and which appears tobe 
shortened also in equine, porcine and mouse IL-4 (Bailey 
et a/., 1993; E.V.Vandergrifft and D.H.Morokov, EMBL 
database accession no. L06010). A specific feature of the 
GM-CSF and IL-2 structures is a short helical segment after 
helix A on the head of the helix bundle, which is not seen 
in human IL-4. It is also interesting to note that the dimeric 
human M-CSF, which represents another 4-helix-bundle 
protein, is connected via the heads of the two protein 
molecules (Pandit et al. 1992). 
Mutational analysis of human IL-2 revealed that aspartic 
acid 20 functions in IL-2 binding to the medium- and high-
affmity receptor (Weigel et al., 1989; Sauve et a/., 1991), 
probably by interacting with the ß subunit of the IL-2 
receptor (IL-2Rß). Similar results have been reported for 
variants of mouse IL-2 with substitutions of aspartic acid 
34 (Zurawski et al., 1990), which corresponds to human 
IL-2 aspartic acid 20. In human GM-CSF, glutamic acid 21 
determines high-affmity binding to the GM-CSF receptor 
(Lopez et al., 1992; Shanafelt and Kastelein, 1992). Because 
low-affinity binding to the GM-CSF receptor a subunit is 
not affected in glutamic acid 21 variants, it was reasonable 
to conclude that this residue interacts directly with the GM-
CSF receptor ß subunit (GM-CSFR,ß). Glutamic acid 9 of 
human IL-4, which has been shown to determine binding 
to IL-4Rex in the present study, is 1ocated at the equivalent 
position to GM-CSF glutamic acid 21 or human IL-2 aspartic 
acid 20 (Wlodawer et al., 1992). On the basis of superficial 
similarities between the amino acid sequences the functional 
equivalence of each of these positions has been postulated 
before (Shanafelt et al., 1991). The present findings support 
the view that an acidic side chain in helix A functions at 
least in the 'small' helical cytokines in binding to a receptor 
subunit. 
Helix C of IL-2 or GM-CSF has not been studied at the 
Two functional sites of human IL-4 
Ievel of single amino acid replacements. Kaushansky (1992) 
identified the sequence between residues 78 and 87 in helix 
C of human GM-CSF as the receptor recognition region. 
Glutamine 86 is located near glutamic acid 21 in the three-
dimensional structure of GM -CSF, like the side chains of 
arginine 88 and glutamic acid 9 in human IL-4. Thus, a 
'binding site' including amino acid side chains from helices 
A and C may be common to these cytokines. lt is tempting 
to speculate that the receptor subunit binding to this site also 
exerts a common function in the various receptor systems. 
This may hold true especially for the extracellular domain 
which binds the Iigand. The fmding that chimeric receptors 
constructed from the intra- and extracellular domains of the 
IL-3Rß and IL-2Rß subunits induce a tyrosine phosphoryla-
tion pattem determined by the extracellular Iigand-binding 
domain (Chiba et a/., 1993) supports this assumption. A 
common functional role would imp1y that the extracellular 
domain of the IL-4 receptor (IL-4ReJ is equivalent to the 
complex ofthat of GM-CSFRa and GM-CSFRß and that 
of IL-2Ra and IL-2R,ß. Theseparated ß subunits of these 
two receptor systems per se have no or only very low binding 
affinity for the ligands. The IL-2Ra subunit binds to amino 
acid residues (arginine 38 and phenylalanine 42) in the small 
helix at the head of human IL-2 (Weigel et al., 1989; Sauve 
et al., 1991). It has been postulated that the GM-CSFRa 
subunit binds to helix D of GM-CSF (Kastelein and 
Shanafelt, 1993) but no experimental data that confirm this 
conclusion have been presented. If the functional and 
structural equivalence ofthe system holds true, GM-CSFRa 
should bind to the head of GM-CSF. 
The receptor subunit binding to the side chains at positions 
121, 124 and 125 in helix D of human IL-4 remains still 
undefmed. In principle, it could be a second molecule of 
IL-4Rex or even a second contact site within IL-4Rex after 
an allosteric conformational change. Up to now it has not· 
been possible to establish IL-4-dependent dimerization of the 
IL-4 receptor or of IL-4Rex (S.Amold et al., unpublished 
observation). No second binding site to IL-4Rex was 
detected in the EC50 variants described in the present 
experiments. Thus, the association with a second, hitherto 
unknown IL-4 receptor subunit appears to be possible. It 
is conceivable that the formation of such a heterodimer ( or 
a higher aggregate of the dimer) represents the signalling 
event which triggers the aggregation of the intracellular 
cytosolic domains (Ullrich and Schlesinger, 1990). Such a 
situation would correspond to a model of the IL-2 system 
which has recently been formulated (for review see Voss 
et al., 1993). An IL-2R-y subunit has been identified which 
appears to interact directly with IL-2 after a contact with 
the complex of the ß plus 'Y subunits ( or a plus ß plus 'Y 
subunits) has been established. This interaction with the 'Y 
subunit probably involves glutamine 141 in helix D ofmouse 
IL-2. Variants affected at this positionexhibitpartial agonist 
activity (lmler and Zurawski, 1992). They are similar in this 
respect to the Rmax variants of human IL-4. 
The results obtained with human IL-4 correspond to 
findings with hGH as far as the existence of two functionally 
distinct sites for receptor (hGH-BP) interactions are 
concemed. Surprisingly, however, they differ with respect 
to the functional role ofthese sites. Growth hormone binds 
two molecules of hGH-BP in an ob Iigatory, sequential two-
step mechanism (Cunningham et al., 1991). The first hGH-
BP binds to site 1 of hGH provided mainly by residues on 
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helix D, and by residues on one side of helix A and in the 
loop region between helices A and B. This first interaction 
of hGH with hGH-BP has a K0 of -200 pM. The 1: 1 
complex between hGH site 1 and hGH-BP then binds in a 
subsequent step a second hGH-BP molecule via site 2. Site 
2 comprises residues on helices A and C (De Vos et al. , 
1992) and from the loop between helices B and C. lt is the 
'signalling site' and determines the efficacy and agonist 
activity of hGH. Accordingly, an antagonistic hGH variant 
(G120R) could be constructed by abolishing binding to site 
2 (Fuh et al., 1992). This bloclcs the receptor activation 
process at the Ievel of the inactive 1: 1 complex. Similarly, 
the receptor system was shifted to the inactive 1: 1 complex 
by a large excess ( > 1 pM) of hGH. In human IL-4 the 
location ofthe 'binding site' and the 'signalling site' appears 
tobe reversed. If a sequential binding mechanism exists also 
in the human IL-4 receptor systems then the frrst step would 
be an interaction via helices A and C of IL-4 and the 
subsequent step would be an interaction via helix D. Such 
a mechanism would, of course, have irnportant irnplications 
for the rational design of high affinity IL-4 antagonists. 
Materials and methods 
Mutsgenesis and Isolation of /L-4 variants 
Mutagenesis of the ll.A cONA was performed either according to the gapped 
duplex method (e.g. K.ruse et al., 1991) or by means of recombinant 
polymerase chain reaction employing two primers complementary for parts 
oftheir 5' and 3' ends (Higuchi, 1990). The manipulated IL-4 cONA was 
expressed in E. coli and the IL-4 variant protein was renatured and highly 
purified as described by K.ruse et al. (1992). Protein concentration was 
determined by measuring absorbance at 280 nm. 
Ouring some experiments, variants E9Q, E9K, R88Q and R880 were 
concentrated to 400 1-'M (6 mg protein/ml) by the following protocol. After 
HPLC, the proteinwas frozen in an alurninium block at -70°C and freeze-
dried under high vacuum ovemight. About 1 mg of the dry, cotton-like 
proteinwas dissolved in 0.1 ml water. The pH was adjusted to 8 by addition 
of20 1-'1 of 1M Tris-acetate, pH 8. The solutionwas dialysed extensively 
against 20 mM Tris-HCI, 1 mM EOTA, pH 8. Protein was diluted to 
6 mglml with the same buffer. The solution was frozen in aliquots at - 20°C. 
Biological assays 
ONA synthesis in peripheral blood cells [largely T -cells (PHA blasts)] was 
determined in duplicate by incorporation of [3H]thymidine. EC50 values 
were calculated from the data obtained in at least three different experiments. 
The EC50 values were distributed log normal. Standard deviations (SO) 
were calculated from log EC50 ± log SO. SO was 1.9-fold for different 
preparations of IL-4, and 2.3-fold of the mean EC50 for all variants except 
E9Q, E9K, R88Q, R880, M1200 and C127D. The SD of the Rmax values 
for IL-4 was ±9; that for all variants except R121D and S1250 was ± 13. 
Induction of C023 in purified B-cells was analysed by fluorescence-activated 
cell sorting (FACScan, Becton-Oickinson) (K.ruse et al., 1992). 
Competitive radio/igand binding 
Iodination of recombinant human IL-4 and binding experiments employing 
Raji cells were performed at least three times in duplicate as described 
elsewhere (K.ruse et al., 1992). The relative IC50 values were distributed 
log normal. Standard deviations (SO) were calculated from log IC50 ± log 
SO. SO was 1.3-fold for measurements with IL-4, and 2-fold of the mean 
IC50 for all variants except E9Q, E9K, R88Q, R880, M1200 and C1270. 
The recombinant extracellular domain of the IL-4 receptor (IL-4Rex> was 
isolated from the supematants of a CHO cell line stably transfected with 
cONA encoding residues -25 to 207 ofthe human IL-4 receptor (S.Amold 
and W.Sebald, unpublished; e.g. Mosley et al., 1989). The IL-4Rex was 
highly purified by affmity adsorbtion to an IL-4- Sepharose 4B matrix and 
by subsequent chromatography on Superose 12 (Pharmacia). The purified 
IL-4Rex was reacted with a 5-fold molar excess of sulfo-NHS-LC-biotin 
(Pierce), and the mixturewas desalted by a passage over BioGel P6 (Bio-
Rad). The biotinylated IL-4Rex was immobilized on streptavidin-coated 
microtitre plates. Saturationbinding of [125J]IL-4 (1.1 x 106 c.p.m./pmol) 
was performed in 0.1 m1 phosphate buffered basal salt, pH 7 .4, plus I% 
BSA at ambient temperature for I h. Competitive radioligand binding assays 
containing 0.2-0.5 nM [12SJ]IL-4 plus serial dilutions of IL-4 variants in 
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the samemedium were incubated as above. Bound 1251 radioactivity was 
determined after three washes with PBS. 
Statist/ca/ evaluations 
All measurements were evaluated by means of the program GraFit (Erithacus 
Software) using the equation y = a/(1 + [Xfi]exps) + back (IC50 - 4 
parameter logistic). A series of dose- response curves from one experiment 
was normalized by the following procedures. The mean values of maximal 
responses (y range) and background (back) were calculated and substituted 
for 'a' and 'back' in the above equation. The slope factor, 's', was assumed 
tobe 1. This yielded the equation: y = y/(1 + [X/J]l) + back. 
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